Empaa is a medication used to treat type 2 diabetes. It is also used to reduce the risk of cardiovascular death in patients with type 2 diabetes and heart or blood vessel disease. Empaa tablet is also used to lower the risk of cardiovascular death and hospitalization in patients with heart failure. The following are some common uses and indications of Empaa Tablet:
  1. Lowering Blood Sugar Levels: Empaa tablet works by blocking the reabsorption of glucose in the kidneys, causing more glucose to be excreted in the urine. This helps lower blood sugar levels in people with type 2 diabetes.
  2. Improving Glycemic Control: Using Empaa tablet can help regulate blood sugar levels, which is essential for managing diabetes.
  3. Reducing Risk of Cardiovascular Events: Clinical trials have shown that Empaa tablet can reduce the risk of major cardiovascular events, including heart attacks, strokes, and cardiovascular-related deaths, in people with type 2 diabetes who are at high risk.
  4. Lowering Blood Pressure: Empaa tablet has been associated with a modest reduction in blood pressure. This can be beneficial for people with high blood pressure, which is a common comorbidity in individuals with type 2 diabetes.
  5. Weight Loss: Some individuals may experience weight loss while taking Empaa tablet. This is due to the loss of excess glucose through the urine.
  6. Protecting Kidney Function: Studies have suggested that Empaa tablet may have protective effects on the kidneys. It may slow the progression of kidney disease in people with type 2 diabetes.
  7. Reducing Risk of Heart Failure Hospitalization: Empaa tablet has been shown to reduce the risk of hospitalization due to heart failure in certain individuals with type 2 diabetes.

Off-label Uses of Empaa Tablet

  1. Polycystic Ovary Syndrome (PCOS): Some studies have investigated the potential benefits of SGLT2 inhibitors like Empaa tablet in women with PCOS, particularly those with insulin resistance.
  2. Chronic Kidney Disease (CKD): There is ongoing research into the potential benefits of Empaa tablets in patients with chronic kidney disease, even those without diabetes. Some studies suggest it may slow the progression of kidney disease.
  3. Weight Management: Due to its mechanism of action in promoting glucose excretion through the urine, Empaa tablet may be considered in certain cases for weight management, although it’s not a primary weight loss medication.
  4. Metabolic Syndrome: Empaa tablet’s effects on glucose metabolism and blood pressure reduction may make it a consideration for patients with metabolic syndrome, a cluster of conditions that increase the risk of heart disease, stroke, and type 2 diabetes.
  5. Non-Alcoholic Fatty Liver Disease (NAFLD): Some research has suggested potential benefits of SGLT2 inhibitors like Empaa tablet in the management of NAFLD, particularly in patients with type 2 diabetes.
Empaa Tablet Uses and Indications

What is Empaa?

Empaa is one of the leading brands of Empagliflozin, manufactured and marketed by Horizon Pharmaceuticals.

Empaa Tablet’s Alternatives : Other Similar Brands

The following are some alternative brands of Empaa and their manufacturers.

  • Jardy : (CCL) Consolidated Chemical Laboratories (Pvt) Ltd, Pakistan.
  • Xenglu : Hilton Pharmaceuticals (Pvt) Ltd, Pakistan.
  • Diajard : Highnoon Pharmaceutical Laboratories (Pvt) Ltd, Pakistan.
  • Diampa : Getz Pharmaceuticals (Pvt) Ltd, Pakistan.
  • Boschempa : Bosch Pharmaceuticals (Pvt) Ltd, Pakistan.
  • Erli : Pharmevo Pakistan (Pvt) Ltd.
  • Empoli : Sami Pharmaceuticals (Pvt) Ltd, Pakistan.
  • Emglif : Genix Pharmaceuticals (Pvt) Ltd, Pakistan.
  • Emsyn : Searle Pakistan Ltd.
  • Empadon : Don Valley Pharma, Pakistan.
  • Jardiance : Boehringer Ingelheim.

Empaa : Available Formulations and Strengths

Presenly, Empaa is available in Tablet Form with the following Strengths.

  • Empaa Tablets : 10mg and 25mg strengths.

Who Should Not Use Empaa? – Contraindications

Empaa tablets have specific contraindications, which means there are situations or conditions where the medication should not be used.

  1. Type 1 Diabetes: Empaa tablet is indicated for the treatment of type 2 diabetes only and should not be used in individuals with type 1 diabetes.
  2. Severe Renal Impairment or End-Stage Renal Disease: Empaa tablet is not recommended for individuals with severe kidney impairment (eGFR less than 30 mL/min/1.73 m²) or those with end-stage renal disease requiring dialysis.
  3. History of Hypersensitivity: Individuals with known hypersensitivity or allergy to Empaa tablet or any of its components should not take this medication.
  4. Pregnancy and Breastfeeding: The safety of Empaa tablets during pregnancy and breastfeeding has not been established. It is generally not recommended for use in pregnant or breastfeeding individuals.
  5. Diabetic Ketoacidosis (DKA): Empaa tablet is not suitable for the treatment of diabetic ketoacidosis, a serious condition that requires immediate medical attention.
  6. Dehydration: Empaa tablet may increase the risk of dehydration, especially in individuals who are elderly, have reduced kidney function, or are taking diuretics. It is important to maintain proper hydration while taking this medication.
  7. History of Lower Limb Amputation: There have been reports of an increased risk of lower limb amputation in patients taking Empaa tablet. It should be used with caution in individuals with a history of lower limb amputation or peripheral vascular disease.
  8. Severe Liver Impairment: The use of Empaa tablet in individuals with severe hepatic impairment has not been studied extensively. It should be used with caution in this population.
  9. Patients Receiving Dialysis: Empaa tablet is not recommended for use in individuals who are on dialysis.

What is the Recommended Daily Dosage of Empaa?

Empaa Tablet Dose for Adults with Type 2 Diabetes:

  • For Monotherapy (taking empagliflozin alone):
    Starting Dose: One tablet of 10 mg, once daily (taken in the morning).
    Your healthcare provider may adjust the dose based on your individual response to the medication.
  • For Combination Therapy (taking empagliflozin with other antidiabetic medications):
    One tablet of 10 mg, once daily (in the morning).
    Again, your healthcare provider may make adjustments based on your specific needs and how you respond to treatment.

If your blood sugar is not adequately controlled with the 10 mg dose, your healthcare provider may increase the dose to 25 mg.

How Empaa Works?

Empaa belongs to a class of drugs known as sodium-glucose cotransporter 2 (SGLT2) inhibitors. SGLT2 is a protein in the kidneys that reabsorbs glucose (sugar) from the urine back into the bloodstream. By inhibiting SGLT2, Empaa prevents the kidneys from reabsorbing as much glucose, allowing excess glucose to be excreted in the urine.